Angiotensin (1-7) prevent heart dysfunction and left ventricular remodeling caused by renal dysfunction in 5/6 nephrectomy mice

Hypertension Research

Volumn 32, Issue 5, 2009, Pages 369-374

  Li, Yiwen ^a   Wu, Jianyong ^a   He, Qiang ^a   Shou, Zhangfei ^a   Zhang, Ping ^a   Pen, Wenhan ^a   Zhu, Yilin ^a   Chen, Jianghua ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN[1-7]; CREATININE; GELATINASE A; GELATINASE B; GENE PRODUCT; HYDRALAZINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROTEIN MAS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CARDIOMYOCYTE HYPERTROPHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; EXPERIMENTAL MOUSE; FIBROSING ALVEOLITIS; HEART DILATATION; HEART DISEASE; HEART FUNCTION; HEART INJURY; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HISTOPATHOLOGY; HYPERTENSION; KIDNEY DYSFUNCTION; MALE; MOUSE; NEPHRECTOMY; NONHUMAN; PROTEIN CONTENT; WILD TYPE;

ANGIOTENSIN I; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CREATININE; HEART FAILURE; HEART VENTRICLES; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MYOCARDIUM; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; RECEPTORS, G-PROTEIN-COUPLED; TRANSFORMING GROWTH FACTOR BETA; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 68249153570     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.25     Document Type: Article

References (42)

1. Foley RN, Parfrey PS, Sarnak M. Cardiovascular disease in chronic renal disease: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 (Suppl 3): S112-s119.
2. Silberberg J, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989; 36: 286-290.
3. Tyralla K, Amann K. Cardiovascular changes in renal failure. Blood Purif 2002; 20: 462-465.
4. Sun Y, Zhang J, Lu L, Bedigian MP, Robinson AD, Weber KT Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart. J Lab Clin Med 2004; 143 41-51.
5. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996; 27: 1201-1206.
6. London GM. Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant 2002; 17 (Suppl 1): 29-36.
7. Brunner HR. Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. Am J Cardiol 2001; 87 (8A): 3C-9C.
8. Toyokuni S, Tanaka T, Hattori Y, Nishiyama Y, Yoshida A, Uchida K, Hiai H, Ochi H, Osawa T. Quantitative immunohistochemical determination of 8-hydroxy-2′-deoxyguanosine by a monoclonal antibody N45.1: Its application to ferric nitrilotriacetate-induced renal carcinogenesis model. Lab Invest 1997; 76: 365-374.
9. Brunner HR. Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. Am J Cardiol 2001; 87: 3Ce9C.
10. Shibasaki Y, Nishiue T, Masaki H, Matsubara H, Iwasaka T. Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD) [in Japanese]. Nippon Rirsho 2002; 60: 1992e8.
11. Ferreira AJ, Santos RAS, Almeida AP. Angiotensin-(1-7): Cardioprotective effect in myocardial ischemia/reperfusion. Hypertension 2001; 38 (part 2): 665-668.
12. Ferreira AJ, Santos RAS, Almeida AP. Angiotensin-(1-7) improves the post-ischemic function in isolated perfused rat hearts. Braz J Med Biol Res 2002; 35: 1083-1090.
13. Loot AE, Roks AJM, Henning RH, Tio RA, Suurmeijer AJH, Boomsma F, van Gilst WH. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 2002; 105: 1548-1550.
14. Peterson MC. Circulating transforming growth factor beta-1: A partial molecular explanation for associations between hypertension, diabetes, obesity, smoking and human disease involving fibrosis. Med Sci Monit 2005; 11: RA229-RA232.
15. Fedulov AV, Ses TP, Gavrisheva NA, Rybakova MG, Vassilyeva JG, Tkachenko SB, Kallner A, MacMillan JC. Serum TGF-beta 1 and TNF-alpha levels and cardiac fibrosis in experimental chronic renal failure. Immunol Invest 2005; 34: 143-152.
16. Okada H, Takemura G, Kosai K, Li Y, Takahashi T, Esaki M, Yuge K, Miyata S, Maruyama R, Mikami A, Minatoguchi S, Fujiwara T, Fujiwara H. Postinfarction gene therapy against transforming growth factor-beta signal modulates infarct tissue dynamics and attenuates left ventricular remodeling and heart failure. Circulation 2005; 111: 2430-2437.
17. Spinale FG. Matrix metalloproteinases: Regulation and dysregulation in the failing heart. Circ Res 2002; 90: 520e30.
18. Heymans S, Schroen B, Vermeersch P, Milting H, Gao F, Kassner A, Gillijns H, Herijgers P, Flameng W, Carmeliet P, Van de Wert F, Pinto YM, Janssens S. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metallo-proteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 2005; 112: 1136e44.
19. Panek AN, Bader M. Matrix reloaded: The matrix metalloproteinase paradox. Hypertension 2006; 47: 640-641.
20. Testa M, Yeh M, Lee P, Fanelli R, Loperfido F, Berman JW, LeJemtel TH. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996; 28: 964-971.
21. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection traction a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll 1996; 27: 1201-1206.
22. Damås A Gullestad L, Aass H, Simonsen S, Fjeld J, Wikeby L, Ueland T, Eiken HG, Frøland SS, Aukrust P. Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure modulatory effects of intravenous immunoglobulin. J Am Coll Cardiol 2001; 38: 187-193.
23. Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Cytokine gene expression after myocardial infarction in rat hearts: Possible implication in left ventricular remodeling. Circulation 1998; 98: 149-156.
24. Deveaux B, Scholz D, Hirche A, Kløverkorn WP, Schaper J. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J 1997; 18: 470-479.
25. Damås JK, Eiken HG, Øie E, Bjerkeli V, Yndestad A, Ueland T, Tonnessen T, Geiran OR, Aass H, Simonsen S, Christensen G, Froland SS, Attramadal H, Gullestad L, Aukrust P. Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure. Cardiovasc Res 2000; 47: 778-787.
26. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone Trial (VEST). Circulation 2001; 103: 2055-2059.
27. Mann DL. Inflammatory mediators and the failing heart: Past, present, and the foreseeable future. Circ Res 2002; 91: 988-998.
28. Deswal A, Misra A, Bozkurt B. The role of anti-cytokine therapy in the failing heart. Heart Fail Rev 2001; 6: 143-151.
29. Oudit GY, Kassiri Z, Patel MP, Chappell M, Butany J, Bacl PH, Tsushima RG, Scholey JW, Khokha R, Penninger JM. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res 2007; 75: 29-39.
30. Keidar S, Kaplan M, Gamliel-Lazarovich A. ACE2 of the heart: From angiotensin I to angiatensin (1-7). Cardiovasc Res 2007; 73: 463-469.
31. Toybkuni S, Tanaka T, Hattori Y, Nishiyama Y, Yoshida A, Uchida K, Hiai H, Ochi H, Osawa T. Quantitative immunohistochernical determination of 8-hydroxy- 2-deoxyguanosine by a monoclonal antibody N45.1: Its application to ferric nitrilotriacetate-induced renal carcinogenesis model. Lab Invest 1997; 76: 365-374.
32. Kinugawa S, Tsutsui H, Hayashidani S, Ide T, Suematsu N, Satoh S, Utsumi H, Takeshita A. Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: Role of oxidative stress. Circ Res 2000; 87 392-398.
33. Suematsu N, Tsutsui H, Wen J, Kang D, Ikeuchi M, Ide T, Hayashidani S, Shiomi T, Kubota T, Hamasaki N, Takeshita A. Oxidative stress mediated tumor necrosis factor α-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation 2003; 107: 1418-1423.
34. Meldrum DR, Dinarello CA, Shames BD, Cleveland Jr JC, Cain BS, - , Meng X, Harken AH. Hydrogen peroxide induces tumor necrosis factor α-mediated cardiac injury by a p38 mitogen activated protein kinase dependent mechanisms. Surgery 1998; 124: 291-296.
35. Nakamura K, Fushimi K, Kouchi H, Mihara K, Miyazaki M, Ohe T, Namba M. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-α and angiotensin II. Circulation 1998; 98: 794-799.
36. Liao XX, Guo RX, Ma H, Wang LC, Chen ZH, Yang CT, Feng JQ. Effects of angiotensin-(1-7) on oxidative stress and functional changes of isolated rat hearts induced by ischemia-reperfusion. Nan Fang Yi Ke Da Xue Xue Bao 2008; 28: 1345-1348. Chinese.
37. Ueda H, Nakamura T, Matsumoto K, Sawa Y, Matsuda H, Nakamura T. A potential cardioprotective role of hepatocyte growth factor in myocardial infarction in rats. Cardiovasc Res 2001; 51: 41-50.
38. Santos RA, Castro CH, Gava E, Pinheiro SV, Almeida AP, de Paula RD, Cruz JS, Ramos AS, Rosa KT, Irigoyen MC, Bader M, Alenina N, Kitten GT, Ferreira AJ. Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor Mas knockout mice. Hypertension 2006; 47: 996-1002.
39. Giani JF, Gironacci MM, Muñoz MC, Turyn D, Dominici FP. Angiotensin-(1-7) has a dual role on growth-promoting signalling pathways in rat heart in vivo by stimulating STAT3 and STAT5a/b phosphorylation and inhibiting angiotensin II-stimulated ERK1/2 and Rho kinase activity. Exp Physiol 2008; 93: 570-578.
40. Su Z, Zimpelmann J, Burns KD. Angiotensin-(1-7) inhibits angiotensin II stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int 2006; 69: 2212-2218.
41. Sampaio WO, Souza dos Santos RA, Faria-Silva R, da Mata Machado LT, Schiffrin EL, Touyz RM. Angiotensin-(1-7) through receptor mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 2007; 49: 185-192.
42. Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol 2005; 289: H1560-H1566.